Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Reinventing Buffer Screening with Avacta’s Optim Technology

Published: Tuesday, March 18, 2014
Last Updated: Monday, March 17, 2014
Bookmark and Share
Optim system screen a wide range of buffer conditions quickly and cheaply.

Avacta’s Optim protein stability analysis technology is helping researchers at Manchester University to approach buffer selection in an entirely new way.

Dr Tom Jowitt, Manager of the University’s Biomolecular Analysis Core Facility, explained: “Academic institutions tend to work by word of mouth on protein projects, sticking to buffer conditions they are familiar with, or that have been used on previous projects within the laboratory. The buffers in use are often far from optimal for the protein of interest, but a lack of understanding of how to optimize buffer conditions means that these issues are rarely addressed.”

“As proteins become easier and easier to make in large quantities, we are trying to promote the concept of buffer screening, encouraging researchers to spend some time optimizing buffer conditions at the start of each project, and this is where Avacta’s Optim instrument comes in. Due to the low sample volume required for each analysis, the Optim system makes it easy to screen a wide range of buffer conditions relatively quickly and cheaply. We can now screen 10 or 20 buffer conditions for a protein of interest in a short space of time, which simply wasn’t plausible before we had the instrument, as the time and labour involved in performing multiple measurements using different technologies for each set of buffer conditions would have been prohibitive. This simple optimization process can have quite a significant impact on protein stability and aggregation rates, particularly for difficult to handle proteins such as those within extracellular matrix. Thanks to the Optim system, the benefits of buffer screening are being widely recognized throughout the Department and, with approximately 250 research groups, the potential knock-on benefits could be highly significant.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!